10-Q: Glaukos Q3 Sales Surge 38% on iDose TR, Epioxa Approved

Glaukos Corporation reported a 38% increase in net sales for Q3 2025, driven by strong iDose TR performance and the recent FDA approval of Epioxa, despite ongoing reimbursement challenges and a net loss.

Summary

• Net sales for the three months ended September 30, 2025, increased by 38% to $133.5 million, up from $96.7 million in the prior year period.
• Net sales for the nine months ended September 30, 2025, increased by 31% to $364.3 million, up from $278.0 million in the prior year period.
• U.S. glaucoma product sales grew 57% to $80.8 million in Q3 2025, primarily due to higher iDose TR volumes, partially offset by lower iStent family product sales.
• International glaucoma product sales increased 20% to $29.4 million in Q3 2025, reflecting broad-based volume growth in key markets like the UK, Japan, France, and Germany, aided by favorable foreign exchange rates.
• Corneal health product sales rose 13% to $23.3 million in Q3 2025, driven by higher Photrexa average sales prices and new account starts, partially offset by Medicaid Drug Rebate Program (MDRP) accruals.
• Net loss for Q3 2025 improved by 24% to $(16.2) million, compared to $(21.4) million in Q3 2024.
• Net loss for the nine months ended September 30, 2025, improved by 52% to $(54.0) million, compared to $(112.8) million in the prior year period.
• Gross margin expanded to 78% in Q3 2025 from 77% in Q3 2024, and to 78% for the nine months ended September 30, 2025, from 76% in the prior year period.
• Operating expenses increased by 23% in Q3 2025 to $121.1 million, primarily due to higher selling, general and administrative (SG&A) expenses related to compensation, stock-based compensation, and commercial infrastructure growth.
• Cash, cash equivalents, short-term investments, and restricted cash totaled $277.5 million as of September 30, 2025, down from $323.6 million at December 31, 2024.
• The company acquired Mobius Therapeutics, LLC for $12.4 million (net of cash acquired) on May 16, 2025, expanding its glaucoma pharmaceutical portfolio with Mitosol.
• The company purchased an adjacent 40,000 square foot building in Aliso Viejo, California, for $16.6 million on April 4, 2025, for future expansion opportunities.

Sentiment

Score: 7

Explanation: The company shows strong revenue growth and significant improvement in net loss, driven by new product launches and international expansion. Key product approvals (Epioxa) and certifications (EU/UK MDR) are positive catalysts. However, it remains unprofitable, faces ongoing reimbursement challenges for existing products, and has a notable cash burn from investing activities, which temper the overall positive sentiment.

Positives

• Strong net sales growth of 38% in Q3 2025 and 31% for the nine months ended September 30, 2025, indicating robust market demand for products.
• Significant improvement in net loss, reducing by 24% in Q3 2025 and 52% for the nine months ended September 30, 2025, demonstrating progress towards profitability.
• Gross margin expanded to 78% in Q3 2025 and for the nine months ended September 30, 2025, reflecting efficient cost management and favorable product mix.
• U.S. glaucoma sales surged 57% in Q3 2025, primarily driven by the successful commercial launch and higher net sales price of iDose TR.
• FDA approval of Epioxa on October 20, 2025, provides a novel, incision-free topical drug therapy for keratoconus, expected to launch in Q1 2026.
• EU and UK MDR certifications for the iStent family of products in June 2025 enable expanded commercialization in key international markets.
• Acquisition of Mobius Therapeutics, LLC expands the glaucoma pharmaceutical portfolio with Mitosol, an FDA-approved mitomycin-C formulation.
• Net cash used in operating activities significantly improved, decreasing from $61.8 million in the nine months ended September 30, 2024, to $21.6 million in the same period of 2025.

Negatives

• Continued net losses, with an accumulated deficit of $799.5 million as of September 30, 2025, indicating the company has not yet achieved sustained profitability.
• Lower volumes of iStent family products in the U.S. glaucoma segment due to Medicare Administrative Contractor (MAC) local coverage determinations (LCDs) restricting combined surgical MIGS procedures.
• Corneal health net sales experienced headwinds from U.S. commercial payer volatility and revenue adjustments related to Medicaid Drug Rebate Program (MDRP) participation.
• Royalty income from the Ivantis/Hydrus Microstent settlement agreement expired on April 26, 2025, removing a previous revenue stream.
• Increased operating expenses, particularly Selling, General and Administrative (SG&A) expenses, which rose 30% in Q3 2025, driven by compensation, stock-based compensation, and commercial infrastructure growth.
• Cash, cash equivalents, and restricted cash decreased by $72.3 million during the nine months ended September 30, 2025, primarily due to investing activities.
• The U.S. government shutdown, ongoing as of October 1, 2025, could impact regulatory agencies like the FDA, potentially delaying regulatory submissions or negatively affecting product sales.

Risks

• Failure to achieve commercial success of iDose TR or Epioxa due to factors like physician adoption, consistent reimbursement, manufacturing capacity, marketing compliance, patient outcomes, and pricing.
• Adverse impact from unfavorable global and regional economic conditions, including inflation, volatility in financial markets, higher interest rates, labor shortages, increased energy costs, and currency fluctuations.
• Potential for supply and/or manufacturing disruptions impacting principal revenue-producing products (iStent family, Photrexa, iDose TR, Epioxa), which could reduce gross margins and negatively impact operating results.
• Inability to reach sustained profitability, given significant accumulated losses and ongoing substantial capital and operating expenditures.
• Failure to generate sufficient sales of commercialized products or to develop and commercialize additional products, potentially leading to obsolescence by competing technologies or lower prices.
• Risks associated with international operations, including differing regulatory approval processes, intellectual property protection, pricing pressures, political instability, and foreign currency fluctuations.
• Product quality or delivery issues could harm reputation, sales, and operating earnings, potentially leading to recalls or product liability suits.
• Ophthalmic surgeons may not adopt products if they do not believe they are safe, efficient, effective, or preferable, or misuse could lead to inferior outcomes.
• Failure to manage anticipated growth effectively could lead to inability to meet customer demand, strain manufacturing capacity, or create product shortages.
• Inability to retain or recruit qualified personnel, including senior management and key employees, could hinder growth plans and strategic objectives.
• Acquisitions, collaborations, or partnerships (e.g., Mobius, licensing agreements) could fail, result in litigation, or not yield expected benefits.
• Cybersecurity incidents, service interruptions, or data corruption could materially disrupt operations, affect business results, or compromise internal controls.
• Failure to comply with data privacy and security laws (e.g., GDPR, CCPA, AI regulations) could result in significant liability, fines, and penalties.
• Net operating loss (NOL) tax carryforwards may not be fully available or subject to limitations to offset future taxable income.
• Future indebtedness could limit cash flow available for operations and adversely affect financial condition.
• Capped call transactions may affect the value of common stock and expose the company to counterparty risk.
• Healthcare legislative reform measures and changes in U.S. and international trade policies (e.g., tariffs, government shutdowns) may materially adversely affect business and results of operations.
• Costly compliance with extensive U.S. and international regulations (FDA, state, foreign authorities), with failure to comply leading to enforcement actions.
• Inadequate or inconsistent reimbursement for products from third-party payors (governmental and commercial) could adversely impact business, including changes in CPT codes or payment rates.

Future Outlook

The company anticipates increased utilization of iDose TR as reimbursement processes become more timely and consistent across Medicare Administrative Contractors (MACs). It expects potential disruption in the U.S. Corneal Health franchise as the market transitions from Photrexa to the newly approved Epioxa, with commercial launch planned for Q1 2026. The company also has a PDUFA date of January 2026 for a supplemental NDA for the re-administration of iDose TR. Long-term plans include developing a new 200,000 square foot R&D and manufacturing facility in Huntsville, Alabama, with construction expected to begin in 2026 and capital expenditures exceeding $80.0 million.

Management Comments

• Management believes the company has sufficient cash to fund operations for at least the next 12 months and the foreseeable future.
• Management acknowledges that the ultimate commercial success of iDose TR and Epioxa depends on factors such as physician training, adoption, consistent reimbursement, manufacturing capacity, and satisfactory patient outcomes.
• Management notes that the U.S. government shutdown, ongoing as of October 1, 2025, could significantly impact the FDA's ability to timely review and process regulatory submissions or negatively affect product sales if prolonged.

Industry Context

Glaukos operates in the highly competitive ophthalmic pharmaceutical and medical technology sector, focusing on innovative solutions for glaucoma, corneal disorders, and retinal diseases. The approval of Epioxa positions the company to disrupt the keratoconus treatment market with an incision-free, topical therapy, potentially setting a new standard of care. The strong performance of iDose TR highlights a growing market acceptance for sustained-release drug delivery systems in glaucoma. However, the industry faces ongoing challenges from evolving reimbursement policies, particularly from Medicare Administrative Contractors (MACs), which can impact product adoption and sales volumes, as seen with the iStent family. The expiration of orphan drug exclusivity for Photrexa and the Ivantis royalty agreement signals increased competitive pressures and the need for continuous innovation. The company's global expansion efforts align with broader industry trends of seeking growth in international markets, but expose it to diverse regulatory and economic risks.

Comparison to Industry Standards

• NA

Corporate Governance

Related Party Transactions

• A member of the Celanese board of directors also sits on the board of directors of the Company, related to the sales agreement for raw materials used in iDose TR.

Stakeholder Impact

• Shareholders: Positive impact from strong revenue growth and improved net loss, but continued unprofitability and cash burn from investing activities may concern some. New product approvals (Epioxa) and pipeline advancements offer future growth potential. Anti-takeover provisions may limit influence on corporate control.
• Employees: Continued investment in R&D and commercial infrastructure suggests job stability and growth opportunities. Stock-based compensation and deferred compensation plans are in place.
• Customers (Ophthalmic Surgeons, ASCs, Hospitals): Benefit from new product approvals like Epioxa and iDose TR, offering advanced treatment options. However, reimbursement complexities and MAC LCDs for iStent products may affect adoption and procedural volumes.
• Suppliers: Ongoing macroeconomic conditions, including inflation and supply chain disruptions, may lead to higher costs and longer lead times, impacting supplier relationships.
• Creditors: The company's working capital position is strong, and management believes it has sufficient liquidity for the foreseeable future, which is favorable for creditors. Future indebtedness could introduce additional obligations.

Next Steps

• Begin commercializing Epioxa in the first quarter of 2026.
• Apply for a permanent HCPCS J-Code for Epioxa and seek coverage by third-party commercial payers.
• Continue efforts to increase iDose TR utilization as reimbursement processes become more timely and consistent across MACs.
• Await Prescription Drug User Fee Act (PDUFA) date of January 2026 for supplemental NDA for re-administration of iDose TR.
• Begin construction of a new 200,000 square foot R&D and manufacturing facility in Huntsville, Alabama, in 2026, with anticipated capital expenditures exceeding $80.0 million.

Key Dates

Recommendation

Glaukos demonstrates strong top-line growth driven by new product adoption (iDose TR) and international expansion, coupled with significant improvements in net loss and gross margin. The recent FDA approval of Epioxa and EU/UK certifications for iStent products are positive catalysts for future revenue streams. However, the company remains unprofitable with a substantial accumulated deficit and is experiencing cash burn from investing activities. Persistent reimbursement challenges for key products and the expiration of a significant royalty income stream introduce headwinds. While the long-term growth trajectory appears promising with pipeline advancements and facility expansion plans, the current unprofitability and market uncertainties warrant a 'hold' recommendation. Investors should monitor the commercial ramp-up of Epioxa, the resolution of iDose TR reimbursement consistency, and progress towards sustained profitability.

Keywords

Glaucoma, Corneal Health, Retinal Disease, Ophthalmic, Medical Technology, Pharmaceutical, MIGS, iDose TR, Epioxa, iStent, Photrexa, FDA Approval, SEC Filing, 10-Q, Financial Results, Biotech, Healthcare, Medical Devices, Drug Delivery